TrialThe Lancet. Infectious diseases2025

Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial.

Nicholas I Paton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.